A pilot study of weekly docetaxel therapy for recurrent ovarian cancer, tubal cancer, and primary peritoneal cancer

We investigated the efficacy and toxicity of salvage chemotherapy with weekly docetaxel for recurrent ovarian cancer, tubal cancer, and primary peritoneal cancer after treatment with regimens containing platinum or paclitaxel. The 15 subjects were managed as outpatients and received at least two courses of docetaxel therapy (35 mg/m2 on days 1, 8 and 15). Antitumour activity was assessed radiologically and from the CA-125 level. Among five patients with measurable lesions, one showed partial remission and three showed stable disease. Based on CA-125 levels, there were three partial remissions and five patients with stable disease (progression-free survival was 7.5 months and 7.6 months, respectively). During 61 courses, the severe toxicities were grade 3 leukopaenia/neutropaenia (6.7%) or grade 2 oedema and pleural effusion (13.3%). Weekly docetaxel may be useful salvage chemotherapy for recurrent ovarian cancer, tubal cancer, and peritoneal cancer, especially as tumour dormancy therapy.

Ovarian cancer; Tubal cancer; Primary peritoneal cancer; Salvage chemotherapy; Weekly docetaxel therapy

[1] Ozols R.F., Bundy B.N., Greer B.E. et al.: "Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study". J. Clin. Oneal., 2003, 21, 3194.

[2] Hainsworth J.D., Burris H.A. 3'', Erland J.B. et al.: "Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer". J. Clin. Oncol., 1998, 16, 2164.

[3] Loffer T.M., Freund W., Droge C. et al.: "Activity of weekly Taxotere in patients with metastatic breast cancer" (abstract). Proc. Am. Soc. Clin. Oneal., 1998, 17, 113a .

[4] Akerley W., Glantz M., Choy H. et al.: "Phase I trial of weekly paclitaxel in advanced lung cancer". J. Clin. Oneal., 1998, 16, 153.

[5] Briasoulis E., Karavasilis V., Anastasopoulos D. et al.: "Weekly docetaxel in minimally pretreated cancer patients: A dose escalation study focused on feasibility and cumulative toxicity of long term administration". Ann. Oneal., 1999, 10, 701.

[6] Kouroussis C., Agelaki D., Mavroudis D. et al.: "A dose escalation study of weekly docetaxel in patients with advanced solid tumors". Cancer Chemother. Pharmacol., 2000, 46, 488.

[7] Hainsworth J.D., Burris H.A. 3'', Litchy S. et al.: "Weekly docetaxel in the treatment of elderly patients with advanced non-small cell lung carcinoma: A Minnie Pearl Cancer Research Network phase II trial". Cancer, 2000, 89, 328.

[8] Burstein H.J., Manola J., Younger J. et al.: "Docetaxel administered on a weekly basis for metastatic breast cancer". J. Clin. Oneal., 2000, 18, 1212.

[9] Hainsworth J.D., Burris H.A. 3'', Yardley D.A. et al.: "Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: A Minnie Pearl Cancer Research Network phase II trial". J. Clin. Oneal., 2001, 19, 3500.

[10] Komiyama S., Mizusawa Y., Onouchi M., Takehara K., Suzuki A., Mikami M.: "Effective weekly docetaxel for recurrent ovarian cancer: A case report". Int. J. Gynecol. Cancer, 2003, 13, 683.

[11] Oken M.M., Creech R.H., Tormey D.C. et al.: "Toxicity and response criteria of the Eastern Cooperative Oncology Group" Am. J. Clin. Oneal., 1982, 5, 49.

[12] Rustin G.J., Nelstrop A.E., Crawford M. et al.: "Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA 125". J. Clin. Oneal., 1997, 5, 172.

[13] Goff B.A., Thompson T., Greer B.E. et al.: "Treatment of recurrent platinum resistant ovarian or peritoneal cancer with gemcitabine and doxorubicin: A phase I/II trial of the Puget Sound Oncology Consortium (PSOC 1602)". Am. J. Obstet. Gynecol., 2003, 188, 1556.

[14] Therasse P., Arbuck S.G., Eisenhauer E.A. et al.: "New guideline to evaluate the response to treatment in solid tumors". J. Natl. Cancer Inst., 2000, 92, 205.

[15] National Cancer Institute common toxicity criteria, Version 2.0 Revised March 23, 1998, http://ctep.info.nih.gov/CTC3/default.htm.

[16] Verschraegen C.F., Sittisomwong T., Kudelka A.P. et al.: "Docetaxel for patients with paclitaxel-resistant Mullerian carcinoma". J. Clin. Oneal., 2000, 14, 2733 Address.